MedStar Health Selected by the AHRQ for Research Partner Network
MedStar Health is proud to announce its selection by the federal Agency for Healthcare Research and Quality (AHRQ) to participate in its research network, known as ACTION IV: Accelerating Change and Transformation in Organizations and Networks. Over the next 5 years, participation in the research network will allow MedStar Health to compete for contracts with an overall value up to $75 million.
MedStar Health to Address High Mortality Rates Among Mothers and Children in Washington, D.C.
MedStar Health has announced a transformative philanthropic partnership with the A. James & Alice B. Clark Foundation to improve care for moms and babies in the Washington D.C. area. The generous commitment establishes the D.C. Safe Babies Safe Moms initiative, which brings together MedStar Health’s nationally recognized experts and clinicians in women’s health, family medicine, behavioral health, and pediatrics.
Interrupting Violence from within the Trauma Unit and Well Beyond
The MedStar Community Violence Intervention Program at MedStar Washington Hospital Center is currently in the midst of a randomized, controlled trial and was recently highlighted in Health Affairs. The study tracks participants for 1 year, comparing the groups in terms of violent injury recidivism, predisposition to violence, substance abuse, and life satisfaction. Participants in the study have been seen at MWHC’s Level I trauma unit either days, weeks, or even months earlier.
Researchers from MedStar Health to Develop AI-Powered Tools in Partnership with IBM for Biologic Product Adverse Events
Researchers from MedStar Health are partnering with IBM to develop a program for post-market safety and effectiveness surveillance for biologic adverse events. At MedStar Health, the work will be led by Aaron (Zach) Hettinger, MD, MS, and Kristen E. Miller, DrPH, CPPS, and will leverage the informatics capabilities of the MedStar Health National Center for Human Factors in Healthcare to support patient outcomes through safety surveillance for the Food and Drug Administration.